These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 8759983)

  • 1. Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery.
    Wilder BJ; Campbell K; Ramsay RE; Garnett WR; Pellock JM; Henkin SA; Kugler AR
    Arch Neurol; 1996 Aug; 53(8):764-8. PubMed ID: 8759983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients.
    Boucher BA; Feler CA; Dean JC; Michie DD; Tipton BK; Smith KR; Kramer RE; Young B; Parks BR; Kugler AR
    Pharmacotherapy; 1996; 16(4):638-45. PubMed ID: 8840370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy.
    Knapp LE; Kugler AR
    J Child Neurol; 1998 Oct; 13 Suppl 1():S15-8; discussion S30-2. PubMed ID: 9796747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intramuscular use of fosphenytoin: an overview.
    Uthman BM; Wilder BJ; Ramsay RE
    Neurology; 1996 Jun; 46(6 Suppl 1):S24-8. PubMed ID: 8649611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intramuscular fosphenytoin (Cerebyx) in patients requiring a loading dose of phenytoin.
    Ramsay RE; Wilder BJ; Uthman BM; Garnett WR; Pellock JM; Barkley GL; Leppik IE; Knapp LE
    Epilepsy Res; 1997 Oct; 28(3):181-7. PubMed ID: 9332883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology and pharmacokinetics of fosphenytoin.
    Browne TR; Kugler AR; Eldon MA
    Neurology; 1996 Jun; 46(6 Suppl 1):S3-7. PubMed ID: 8649612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.
    Fischer JH; Patel TV; Fischer PA
    Clin Pharmacokinet; 2003; 42(1):33-58. PubMed ID: 12489978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of fosphenytoin sodium.
    Fierro LS; Savulich DH; Benezra DA
    Am J Health Syst Pharm; 1996 Nov; 53(22):2707-12. PubMed ID: 8931812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin.
    Coplin WM; Rhoney DH; Rebuck JA; Clements EA; Cochran MS; O'Neil BJ
    Neurol Res; 2002 Dec; 24(8):842-8. PubMed ID: 12500711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetic Analysis of Phenytoin After Intravenous Administration of Fosphenytoin in Adult and Elderly Epileptic Patients.
    Higuchi K; Yamashita D; Kashihara Y; Kakara M; Hirota T; Hirakawa M; Ieiri I
    Ther Drug Monit; 2019 Oct; 41(5):674-680. PubMed ID: 31095070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of fosphenytoin for the treatment of status epilepticus.
    Popławska M; Borowicz KK; Czuczwar SJ
    Expert Rev Neurother; 2015; 15(9):983-92. PubMed ID: 26289487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fosphenytoin (Cerebyx).
    Browne TR
    Clin Neuropharmacol; 1997 Feb; 20(1):1-12. PubMed ID: 9037568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fosphenytoin: a novel phenytoin prodrug.
    Boucher BA
    Pharmacotherapy; 1996; 16(5):777-91. PubMed ID: 8888074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of phenytoin following intravenous and intramuscular administration of fosphenytoin and phenytoin sodium in the rabbit.
    Muchohi SN; Kokwaro GO; Maitho TE; Munenge RW; Watkins WM; Edwards G
    Eur J Drug Metab Pharmacokinet; 2002; 27(2):83-9. PubMed ID: 12064376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous administration of fosphenytoin: options for the management of seizures.
    Ramsay RE; DeToledo J
    Neurology; 1996 Jun; 46(6 Suppl 1):S17-9. PubMed ID: 8649609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus.
    Ogutu BR; Newton CR; Muchohi SN; Otieno GO; Edwards G; Watkins WM; Kokwaro GO
    Br J Clin Pharmacol; 2003 Jul; 56(1):112-9. PubMed ID: 12848783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteers.
    Tanaka J; Kasai H; Shimizu K; Shimasaki S; Kumagai Y
    Eur J Clin Pharmacol; 2013 Mar; 69(3):489-97. PubMed ID: 22918614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of intravenous fosphenytoin sodium in healthy Japanese volunteers.
    Inoue Y; Usui N; Hiroki T; Shimizu K; Kobayashi S; Shimasaki S
    Eur J Drug Metab Pharmacokinet; 2013 Jun; 38(2):139-48. PubMed ID: 22968854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenytoin pharmacokinetics following oral administration of phenytoin suspension and fosphenytoin solution to rats.
    Burstein AH; Cox DS; Mistry B; Eddington ND
    Epilepsy Res; 1999 Apr; 34(2-3):129-33. PubMed ID: 10210027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fosphenytoin.
    Luer MS
    Neurol Res; 1998 Mar; 20(2):178-82. PubMed ID: 9522355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.